Upload
others
View
7
Download
0
Embed Size (px)
Citation preview
Immuno-Oncology (IO) in Non-Small Cell Lung Cancer (NSCLC)A clinical review of the competitive landscape, approved therapies, trial outcomes and experienced investigators in this highly targeted space.
Top 10 Sponsors of Active IO NSCLC Trials
Trial Breakdown by Phase and Status
Where are these trials taking place?
The Competitive Landscape
Source: Trialtrove® September 2018
LOCATIONS NUMBER OF TRIALSUnited States 344Spain 107Canada 91France 90Japan 81Australia 80United Kingdom 77South Korea 70Germany 69Italy 65China 63Netherlands 52Taiwan 46Belgium 45Poland 37
10
92
81
51
39
30
18
18
1714
Bristol-Myers SquibbMerck & Co.RocheAstraZenecaOno Pharmaceutical
IncyteNovartisPfizerEli LillyCelgene
200
150
100
50
0
Tria
l cou
nt
Planned Open Closed
I I/II II II/III III III/IV IV
Bristol-Myers Squibb and Merck are the leading
sponsors of active IO NSCLC trials, as developers of the top PD-1 inhibitors, Opdivo
and Keytruda
Trial activity is primarily in three major geographical regions: North America, Europe and Asia. Trials
conducted in recent years have seen a slight
shift towards the East
87% of all industry-sponsored, ongoing or
planned IO NSCLC trials are early stage
(Phase I–II)
**Pipeline investment is predominantly focused on PD-1 agents with IDO inhibition being trialed as a new IO approach
95Opdivo
71Keytruda
39Tecentriq
27Imfinzi
21Yervoy
What are the top 5 approved IO therapies, ranked by number of active NSCLC studies?
PD-1 antagonist CTLA-4 antagonistPD-L1 antagonist
Source: Trialtrove® September 2018
Major takeaways from trial outcomes:
Trials evaluating PD-1/PD-L1 inhibitors represent 84% of all IO NSCLC trials
PD-1 and PD-L1 antagonist therapies dominate the leading approved drugs based on the number of active trials for NSCLC
Out of 37 trials in Trialtrove with confirmed outcomes, 29 achieved positive results, three of which completed early due to positive outcomes (CheckMate-078, Keynote-024 and Keynote-189).
Lack of efficacy was the main reason for trial failures: four primary endpoint misses and two early terminations. Additionally, two trials were terminated due to safety findings.
Global Distribution of Sitetrove Investigators
South America: 177 (3.5%)
North America: 2382 (47%)
Africa: 3 (<.01%)
Western Asia/Middle East:
35 (.7%)
AsiaPAC: 963 (19%)
Eastern Europe: 294 (5.8%)
Western Europe: 1216 (24%)
38% of these investigators are *not* currently tied to an ongoing or planned IO NSCLC trial and may be suitable candidates to take on new trials in this space
Source: Sitetrove® September 2018
5070 investigators are experienced in industry-sponsored IO NSCLC trials, globally.o More than half of these investigators are located in the Americas alone,
while the remainder are largely spread across Europe and AsiaPAC.o Less than 1% of these investigators fall within Western Asia,
the Middle East and Africa.
Pharma Intelligenceinforma
Report available: The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC) CLICK HERE
Pharma intelligence informa